Paracetamol SAM

Quick links to important sections

Paracetamol SAM

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Paracetamol SAM

Quick Facts

Property Description
Active Ingredient Acetaminophen (Paracetamol)
Pharmacological Class Analgesic and Antipyretic
Form Pharmaceutical preparation (e.g., tablet, liquid)
Common Use Relief of general pain and reduction of fever
Origin Synthetic compound

What is the Pharmacological Classification of Paracetamol SAM?

Paracetamol SAM is a medicinal product defined by its active ingredient, Acetaminophen, which is recognized internationally by the generic name Paracetamol. It is classified pharmacologically as both an analgesic (pain reliever) and an antipyretic (fever reducer), and it belongs to the Para-aminophenol derivative chemical group. This compound is typically available as a non-prescription or Over-the-Counter (OTC) medicine.


The product functions as a monotherapy, containing only the single active substance, Acetaminophen, which distinguishes it from combination formulations. The efficacy profile is recognized for managing common symptomatic discomfort.

Composition, Origin, and Available Forms

The active substance, Acetaminophen, is a synthetic compound, manufactured entirely through controlled chemical processes. The specific composition of Paracetamol SAM formulations includes Acetaminophen alongside necessary inactive excipients that form the final pharmaceutical preparation.


This specific brand or product line may feature differentiated characteristics, such as specialized dosage forms or unique liquid formulations, though the core chemical remains the same. The common route of administration for these forms is oral, with preparations typically existing as tablets or solutions. The principal action of the substance is classified based on its distinct pain-relieving and temperature-lowering effects.

The General Therapeutic Purpose of Acetaminophen

The general therapeutic purpose of Paracetamol SAM is to provide effective pain relief and contribute to the essential reduction of fever.


This medication offers symptomatic relief by mitigating general discomfort and aiding the body in lowering an abnormally high core temperature. The primary benefit of this analgesic-antipyretic profile is providing targeted, foundational symptomatic management.

Regulatory References

  1. Acetaminophen: MedlinePlus Drug Information

What side effects are possible with Paracetamol SAM?

Possible Side Effects and Safety Information

The official safety profile for Paracetamol is defined by the regulatory classification of documented adverse reactions, which are generally rare at recommended therapeutic doses. The risk assessment focuses primarily on rare but potentially serious systemic events, rather than common effects.

Officially Documented Adverse Reactions

Adverse effects are categorized by frequency, with the majority of clinically significant reactions falling into the Rare or Very Rare classifications according to official regulatory data.

Classification Examples of Effects by System-Organ Class
Very Rare Serious Skin Reactions (e.g., SJS, TEN, AGEP), Blood Dyscrasias (e.g., thrombocytopenia), Anaphylactic Shock.
Rare Hypotension, increased hepatic transaminases, general malaise.

High-Level Safety Constraints

The most significant safety constraint documented by regulatory authorities concerns the potential for Severe Hepatic Injury and Acute Liver Failure, which is dose-dependent and heightened by overdose. Official prescribing information explicitly warns against the concurrent use of Paracetamol SAM with any other products containing the same active ingredient, as this cumulatively increases the risk of severe liver damage.

Safety notes for specific populations include explicit caution for individuals with Severe Hepatic Impairment or Severe Renal Impairment. The official labeling also recognizes conditions such as chronic alcoholism, malnutrition, and glutathione deficiency as risk factors that may predispose an individual to hepatic adverse reactions.

Overdose and Emergency Response

Overdose Manifestations and Severity

Overdose of Paracetamol SAM may initially present with non-specific symptoms such as nausea, vomiting, anorexia, and excessive diaphoresis. These initial signs are often transient, but their resolution does not indicate safety or preclude the development of severe toxicity. The principal documented manifestation of overdose is acute hepatic necrosis, which can progress to life-threatening outcomes including hepatic failure, metabolic acidosis, and hepatic encephalopathy. Officially documented clinical indicators include abdominal pain and laboratory findings showing significantly elevated hepatic transaminases ( AST and ALT) and an increased International Normalized Ratio ( INR). Increased susceptibility to severe toxicity is noted in official documents for patients with pre-existing hepatic impairment or a history of chronic heavy alcohol consumption.

Regulator-Mandated Emergency Actions

Regulatory labeling mandates that all individuals seek immediate medical attention by contacting emergency services or a poison control center immediately upon suspected overdose. This urgent intervention is required irrespective of the presence or absence of initial symptoms, due to the critical latent risk of severe, delayed liver damage. The official antidote, N-acetylcysteine (NAC), is formally indicated for use and must be administered promptly in a clinical setting. Management requires close medical observation, often including hospital monitoring, serial liver function testing, and the measurement of plasma acetaminophen concentration to accurately assess the extent of exposure.

Therapeutic Uses of Paracetamol SAM

What Paracetamol SAM Treats: Main Uses and Benefits

The therapeutic use of Paracetamol SAM aligns with the indications for its active ingredient. It is commonly used in contexts marked by increased discomfort or tension, providing symptomatic assistance and contributing to easing the overall symptom load.


Foundational Symptom Management

Paracetamol SAM is primarily considered relevant for easing symptoms related to physical discomfort and elevated core body temperature (fever). It supports easing the overall symptom burden, contributing to improved comfort during periods when symptoms related to heightened physiological activity intensify. The medication is commonly used across conditions involving episodic or fluctuating manifestations, such as tension headaches, musculoskeletal aches, dental pain, and the systemic symptoms linked to the common cold and influenza.

Supportive Use in Acute Scenarios

This medication is relevant when supportive symptom management is appropriate in specific scenarios where symptoms interfere with daily functioning. This includes easing pain and fever that may occur following immunization (vaccination reactions) or managing the episodic pain of primary dysmenorrhea (menstrual cramps). It may assist with managing symptoms that become temporarily overwhelming, contributing to a more manageable experience during these acute phases.


Key Fact: Symptom Support
Primary Benefit Offers symptomatic relief that helps patients cope more steadily
Symptom Focus Symptoms that create noticeable physiological strain
Typical Contexts of Use Acute episodes, seasonal illness, post-immunization

Eligibility and Restrictions for Use

Who can and cannot use Paracetamol SAM

Official regulatory documents establish clear eligibility boundaries for Paracetamol (Acetaminophen) use, based on specific health status and age.

Eligibility Status Population Group
Contraindicated (Must Not Use) Individuals with documented hypersensitivity to Paracetamol or any excipients. Patients diagnosed with severe hepatic impairment or active liver disease.
Restricted/Conditional Use Patients with severe renal impairment require use with caution and a label-mandated extension of the dose interval. Individuals with chronic alcoholism or chronic malnutrition are classified as high-risk, requiring special caution.

Age and Reproductive Status

Age-Related Eligibility: Use is generally permitted for adults and adolescents who are free of contraindications. Pediatric labeling establishes a minimum age threshold for use, with the drug not recommended for infants below this specific limit. Use in children is strictly based on body weight.

Pregnancy and Lactation: Official guidance permits use during pregnancy, but mandates adherence to the principle of the lowest effective dose for the shortest possible duration. Use while breastfeeding is generally considered compatible at standard therapeutic doses.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documentation identifies specific patterns that constrain the co-administration of Paracetamol SAM (Acetaminophen).

Formal Interaction Restrictions

The co-administration of Paracetamol SAM with any other medicinal product containing acetaminophen is formally prohibited to prevent accidental exceeding of the maximum daily dose, which is associated with the risk of severe hepatic injury. The product is also contraindicated in patients with pre-existing severe hepatic impairment or severe active liver disease, confirming a critical population-dependent restriction.


Documented Pharmacodynamic and Metabolic Effects

The most significant interaction concerns coumarin anticoagulants, such as Warfarin. Official data shows that chronic, higher-dose co-administration has the potential to cause an increase in the International Normalized Ratio (INR), thereby potentiating the anticoagulant effect. Additionally, co-administration with substances that regulate or induce the CYP2E1 enzyme is noted to increase the potential for hepatotoxicity due to altered metabolic processing. Chronic, heavy consumption of alcohol is also subject to a formal regulatory warning due to the significantly heightened risk of severe liver damage.


Population-Specific Constraints

Use in patients with severe renal impairment (creatinine clearance le 30 mL/min) is linked to a regulatory note that longer dosing intervals or a reduced total daily dose may be necessary. Other conditions like chronic malnutrition or severe hypovolemia are officially noted as increasing the potential for hepatotoxicity.

Mechanism of Action

The drug, Paracetamol SAM, exerts its action primarily within the central nervous system (CNS) through several distinct mechanisms.


Central Cyclooxygenase Inhibition

The drug engages enzyme-mediated signaling pathways by weakly inhibiting the activity of cyclooxygenase (COX) enzymes, particularly within the CNS. This action interferes with the synthesis of prostaglandins (e.g., PGE2) in the brain's thermoregulatory center (hypothalamus). This mechanistic cascade contributes to the attenuation of prostaglandin synthesis within the hypothalamic thermoregulatory center and the modification of neuronal hyperexcitability.


Endocannabinoid and Vanilloid Receptor Modulation

Paracetamol is metabolized in the CNS to a bioactive component, AM404, which acts within domains involving receptor-mediated signaling. This metabolite activates the transient receptor potential vanilloid-1 (TRPV1) receptor and influences the cannabinoid-1 (CB1) receptor systems. Engaging these mechanisms modifies early molecular steps that regulate ascending nociceptive signals, resulting in the modification of signal transduction associated with nociception.


Descending Serotonergic Pathway Potentiation

Paracetamol's action is relevant in systems where targeted pathway adjustment is required by potentiating the activity of the descending inhibitory serotonergic pathway. This pathway originates in the brainstem and modulates pain transmission within the spinal dorsal horn. This pathway modulation influences the balance of inhibitory and excitatory signaling, leading to an alteration in descending pain signal transmission.

Dosage and Administration Information

How to Use Paracetamol SAM: Administration Guidelines

The usage of Paracetamol SAM, containing acetaminophen, follows standardized methods, frequency, and maximum amounts for administration.


Administration Scope

Instruction Detail
Route of Administration The approved routes include Oral (tablets, solutions), Rectal (suppositories), and Intravenous (IV), with the IV route typically reserved for hospital settings.
Dosing Schedule (Adults ge 50 kg) Standard single doses range from 325 mg to 1000 mg. The critical ceiling is the total daily dose, which should not exceed 4000 mg in a 24-hour period from all sources.
Frequency and Interval Doses may be repeated every 4 to 6 hours as required, provided the mandated minimum interval is maintained and the 24-hour maximum is not surpassed.

Procedural and Population Constraints

The correct use protocol requires adherence to specific administration rules based on formulation and patient status.

Instruction Detail
Preparation and Handling Oral suspensions must be shaken well before use. Extended-release forms must be swallowed whole and must not be crushed. IV solutions, when used, must be administered as a 15-minute intravenous infusion.
Population Adjustments Dosing for pediatric patients is based on body weight. For adults with severe renal impairment, the minimum interval between doses must be increased to at least 6 hours to accommodate altered clearance.
Course Duration Use is generally limited to a short duration; guidelines suggest seeking professional guidance if use exceeds 10 days for pain or 3 days for fever.

Connection to the overall use protocol: These standardized parameters define the necessary limits—the route, the precise amount, and the critical time intervals—that guide the use of Paracetamol SAM. Adherence to these limits is essential for proper administration.

Recent Clinical Evidence

Research evidence / Overview of studies for Paracetamol SAM

Evidence for Use in General Acute Pain and Discomfort

Research has extensively examined the substance's use for outcomes related to physical discomfort across various mild to moderate acute pain episodes. Studies, primarily short-term Randomized Controlled Trials (RCTs) and meta-analyses, was evaluated in adults, adolescents, and children experiencing pain. These trials focused on outcomes describing episodic or acute changes, specifically by monitoring the change in pain intensity using measured scales and documenting the time to a measured shift in symptoms. The need for rescue medication was also a measured outcome.

The research describes measured changes during the short study period, often comparing the substance to an inactive control. Findings describe patterns observed in the studies focused mostly on the initial, earliest measured phase of pain change.

Research on Fever Reduction (Antipyretic Evidence)

The substance was studied for research on elevated core body temperature, or fever. These studies included controlled trials and systematic reviews evaluating its use in a broad population range, including infants, children, and adults. The research focused on outcomes related to systemic imbalance or changes in body function by monitoring absolute body temperature changes in degrees Celsius and the duration of any measured temperature-lowering effect.

Findings indicate a measured temporary change in core body temperature in individuals observed in some studies. This evidence describes symptom patterns primarily over very short durations.

The Current Research Landscape for Specific Low Certainty Indications

Research explored the substance in studies of conditions characterized by fluctuating or episodic manifestations, particularly chronic musculoskeletal pain such as osteoarthritis. Comparative evidence describes patterns of measured outcomes that were reported as modest relative to other available treatments for these chronic conditions. Furthermore, when the substance was evaluated in studies for specific acute conditions, such as non-specific low back pain, the most robust evidence describes patterns that showed no measured difference in primary outcomes (such as pain scores or function) when compared to an inactive control. The overall evidence quality varies across studies for these indications, leading to low certainty in overall conclusions.

Evidence in Specific Populations and Research Gaps

Long-term effects are not fully established regarding the substance, as the follow-up durations were limited in many of the key trials. Data for certain groups remain insufficient, particularly for individuals with specific comorbid conditions, meaning subgroup findings are uncertain. The overall evidence landscape features documented limitations, and more research is ongoing to address these uncertainties.

Key Studies & References NICE Guideline: Non-specific low back pain and sciatica: assessment and management

Frequently Asked Questions (FAQ)

Common questions about Paracetamol SAM (FAQ)


Q: What are the most commonly reported side effects people notice after taking Paracetamol SAM?

A: Official regulatory documents place a strong focus on rare and very rare serious adverse reactions, such as severe skin reactions, anaphylactic shock, and blood disorders. These summaries do not typically detail milder, more common side effects. The specific range of possible common effects is often found in the patient information leaflet that accompanies the medicine.

Q: Can Paracetamol SAM cause an allergic reaction, and what are the warning signs?

A: Yes, official labeling notes that Paracetamol can cause severe skin and allergic reactions, and its use is contraindicated (must not be used) if a person has a documented hypersensitivity to it. Warning signs that warrant immediate medical evaluation or attention include skin reddening, rash, blisters, swelling of the face, or difficulty breathing.

Q: Is it normal to feel a bit dizzy or drowsy after taking a dose of Paracetamol SAM?

A: Dizziness or drowsiness are not generally listed as common side effects in the official regulatory safety profiles, which prioritize rare, serious events. While the list does include general malaise, if a person experiences sudden confusion, dizziness, or unusual drowsiness, this may be a sign of a serious allergic reaction or an overdose and warrants immediate medical evaluation.

Q: What is the expected duration of pain relief from one tablet of Paracetamol SAM?

A: The recommended dosing interval, typically every 4 to 6 hours, reflects the window during which the drug is active. The peak concentration of the medicine in the blood is usually reached within an hour after taking an oral dose.

Q: Does Paracetamol SAM affect blood clotting or interact with blood thinning medications?

A: Official information confirms that Paracetamol has a documented interaction with coumarin anticoagulants (such as Warfarin). Chronic use of Paracetamol at higher doses has the potential to cause an increase in the International Normalized Ratio (INR), which may potentiate the anticoagulant effect.

Q: Is Paracetamol SAM safe for use during pregnancy or while breastfeeding?

A: Regulatory documents indicate that Paracetamol may be used during pregnancy when needed, recommending adherence to the lowest effective dose for the shortest possible duration. Use while breastfeeding is noted to be acceptable when the medicine is taken at standard therapeutic doses.

Q: Why do some people say Paracetamol SAM is safer for the stomach than aspirin?

A: Official documents indicate that Paracetamol primarily works in the central nervous system, and unlike some other pain relievers, it is not generally associated with causing gastric irritation or bleeding. This distinction is based on the mechanism of action described in regulatory texts.

Q: What should I do if I suspect I have taken more Paracetamol SAM than recommended?

A: If an overdose is suspected, official warnings stress the essential need to seek medical evaluation immediately, even if the person currently feels well. This requires contacting emergency services or a Poison Control Center right away, as severe hepatic injury may be delayed up to 48 hours after ingestion.

Q: Why is it important to keep Paracetamol SAM out of reach of children?

A: It is a mandatory regulatory instruction to keep this product out of the reach and sight of children. This is because accidental overdose of Paracetamol is recognized as a leading cause of preventable acute liver failure, and proper child dosing requires precise weight-based calculation.

Q: If my symptoms don't improve after a few days, does that mean Paracetamol SAM is not working for me?

A: Official labeling instructs that a person should stop taking the product and seek professional medical guidance if pain persists for more than 10 days, or if a fever lasts more than 3 days. Lack of improvement within these short timeframes can indicate a more serious underlying condition that warrants medical attention.

Q: Will taking Paracetamol SAM affect the performance of my other regular medications?

A: Paracetamol has documented interactions with other medicines, most notably with coumarin anticoagulants and any product containing acetaminophen itself. Official guidance emphasizes the importance of informing a healthcare provider about all prescription or over-the-counter medicines, vitamins, and herbal products being used.

Q: Can Paracetamol SAM be used for mild arthritis or joint pain?

A: Paracetamol is generally indicated for the relief of mild to moderate pain. While studies have explored its use for chronic musculoskeletal pain, such as osteoarthritis, the evidence for these specific chronic conditions is noted to be of low certainty. Its primary use remains for general symptomatic pain relief.

Q: Does the time of day matter when taking Paracetamol SAM?

A: Regulatory guidance focuses strictly on maintaining the appropriate interval between doses, which is typically every 4 to 6 hours, and ensuring the maximum 24-hour limit is not exceeded. The specific time of day (such as morning versus evening) is not designated as a factor in administration.

Q: Are headaches that worsen after taking Paracetamol SAM a recognized, but rare, side effect?

A: While Paracetamol is used for headache relief, official classification systems recognize that regular, frequent use of any acute pain medication can lead to a condition called 'Medication-Overuse Headache' in susceptible individuals. The labeling advises that use should be limited to short-duration protocols.

Q: Why might a doctor prescribe Paracetamol SAM even though it's available over-the-counter?

A: Doctors may prescribe the product for conditions listed in the official therapeutic indications or when specialized routes of administration, such as an Intravenous (IV) infusion, are needed in a hospital setting. Prescription may also be used to facilitate its co-administration with other required pain relievers.

Q: Can taking Paracetamol SAM for a long time mask symptoms of a more serious issue?

A: Official warnings specify that a person should seek medical advice if pain or fever persists longer than the recommended short duration (3 to 10 days). This warning is intended to prevent the prolonged use of the drug from masking or delaying the accurate diagnosis of a potentially serious underlying condition.

Q: If I accidentally miss a dose of Paracetamol SAM, what is the guidance?

A: Consumer information from regulatory sources generally states that if a scheduled dose is missed, it may be taken as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose should be skipped to prevent exceeding safety limits, and the regular dosing schedule should be resumed. Doses should not be doubled.

Q: Does Paracetamol SAM interact with any common herbal supplements?

A: Regulatory guidance emphasizes that a person should inform their doctor or pharmacist about all herbal products and supplements being used. This is necessary because some supplements may interact with Paracetamol by potentially altering its metabolism or increasing the risk of liver toxicity.

Q: Is the effectiveness of Paracetamol SAM the same across different age groups?

A: Regulatory data supports the use of the drug across various age groups when appropriate weight-based or age-based guidelines are followed. However, dosing for children is strictly based on body weight, as the metabolism of the drug can differ in younger children compared to adults.

Q: Can Paracetamol SAM be used in combination with prescription pain medications?

A: Official warnings formally prohibit the co-administration of Paracetamol SAM with any other product that contains acetaminophen, including certain combination prescription painkillers. For co-administration with other classes of prescription pain medications, seeking professional medical guidance is necessary to assess potential drug-drug interactions.

How should Paracetamol SAM be stored and disposed of?

How to Store and Dispose of Paracetamol SAM

The storage and disposal of paracetamol (acetaminophen) must strictly follow the official conditions documented in regulatory labeling to maintain stability and ensure safety.


Storage Requirements

Item Regulatory Requirement
Temperature Store at controlled room temperature, typically 20 C to 25 C (68 F to 77 F). Do not freeze the product.
Protection Protect from light and moisture. Keep the medicine in its original container and keep it tightly closed.
Child Safety Mandatory instruction to keep out of the reach and sight of children.

Disposal Instructions

Expired or unused product must be disposed of according to local requirements for pharmaceutical waste, such as approved take-back programs. Official guidelines advise against disposing of paracetamol in wastewater (flushing down the toilet or sink) or regular household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Paracetamol SAM found in:

A-Z Index: